N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion

A recently approved peptidic human immunodeficiency virus type 1 (HIV-1) fusion inhibitor, T-20 (Fuzeon; Trimeris Inc.), has shown significant promise in clinical application for treating HIV-1-infected individuals who have failed to respond to the currently available antiretroviral drugs. However,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Jiang, Shibo, Lu, Hong, Liu, Shuwen, Zhao, Qian, He, Yuxian, Debnath, Asim K.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2004
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC525433/
https://ncbi.nlm.nih.gov/pubmed/15504864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.11.4349-4359.2004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares